Ocular Therapeutix (OCUL) Research & Development (2016 - 2025)
Historic Research & Development for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $50.8 million.
- Ocular Therapeutix's Research & Development rose 2393.57% to $50.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $197.1 million, marking a year-over-year increase of 5442.16%. This contributed to the annual value of $197.1 million for FY2025, which is 5442.16% up from last year.
- As of Q4 2025, Ocular Therapeutix's Research & Development stood at $50.8 million, which was up 2393.57% from $52.4 million recorded in Q3 2025.
- Ocular Therapeutix's Research & Development's 5-year high stood at $52.4 million during Q3 2025, with a 5-year trough of $10.9 million in Q1 2021.
- Its 5-year average for Research & Development is $24.5 million, with a median of $15.1 million in 2023.
- Its Research & Development has fluctuated over the past 5 years, first crashed by 547.66% in 2022, then soared by 15309.66% in 2024.
- Ocular Therapeutix's Research & Development (Quarter) stood at $12.6 million in 2021, then grew by 7.67% to $13.5 million in 2022, then rose by 19.58% to $16.2 million in 2023, then soared by 153.1% to $41.0 million in 2024, then grew by 23.94% to $50.8 million in 2025.
- Its Research & Development stands at $50.8 million for Q4 2025, versus $52.4 million for Q3 2025 and $51.1 million for Q2 2025.